The MOTS-C peptide is unusual even within peptide research. Rather than being encoded primarily by nuclear DNA, MOTS-C originates from a short open reading frame within mitochondrial DNA—the separate genetic material found inside mitochondria.
Since researchers first characterized it in 2015, MOTS-C has attracted attention for its possible role in metabolic homeostasis, insulin sensitivity, exercise adaptation, cellular stress responses, and age-related physical decline. But the evidence needs to be read carefully: most intervention studies are still based on cells and animal models, while direct human research remains much more limited.
If you are investigating mitochondrial-derived peptides in a laboratory setting, explore Research Peptides Canada for research-use-only compounds and available product documentation. Understanding where the evidence comes from is particularly important with MOTS-C because endogenous human observations and experimental peptide administration are not the same thing.
What Is MOTS-C Peptide?
The MOTS-C peptide is a 16-amino-acid mitochondrial-derived peptide, commonly abbreviated as an MDP. Its full name is mitochondrial open reading frame of the 12S rRNA type-c.
Researchers first described MOTS-C in detail in 2015 after identifying a short open reading frame inside the mitochondrial 12S rRNA gene, MT-RNR1.
In the foundational study, Lee and colleagues found that MOTS-C affected metabolic homeostasis and insulin sensitivity, with skeletal muscle appearing to be a major target tissue. In mice, experimental MOTS-C administration also reduced high-fat-diet-induced insulin resistance and obesity. (Lee et al., 2015, Cell Metabolism)
One important detail is that MOTS-C belongs to a broader group of small signaling molecules encoded by mitochondrial DNA. These mitochondrial-derived peptides include molecules such as humanin and several small humanin-like peptides.
So, when you think about the MOTS-C peptide, it is more useful to view it as part of a mitochondrial signaling system than as simply another conventional synthetic research peptide.
Interested in exploring this compound further? Learn more about MOTS-C 10mg for research purposes.
Why Is MOTS-C Different From Most Other Peptides?
Most human peptide hormones and proteins are encoded by genes located in the nucleus.
MOTS-C peptide is different because its genetic sequence originates from mitochondrial DNA.
That gives the peptide an unusual place in cellular biology. Mitochondria are best known for generating cellular energy, but MOTS-C research suggests that they can also produce signaling molecules capable of communicating metabolic information to other parts of the cell.
The distinction became even more interesting in 2018.
Kim and colleagues demonstrated that MOTS-C could move from the cytoplasm into the cell nucleus during metabolic stress, including glucose restriction. Once inside the nucleus, it influenced expression of stress-response genes through pathways involving AMPK and transcription factors such as NRF2. (Kim et al., 2018, Cell Metabolism)
A subsequent review described this process as a form of mitonuclear communication—communication from mitochondria back toward the nucleus. (Benayoun & Lee, 2019, BioEssays)
This is one reason the MOTS-C peptide has become particularly interesting in aging and stress-response research. Instead of functioning only as an extracellular signal, MOTS-C may also influence how cells adjust gene expression when metabolic conditions change.
What Does MOTS-C Do in the Body?
Current evidence suggests that MOTS-C is involved primarily in metabolic regulation and adaptation to cellular stress.
One of the best-characterized pathways involves AMPK, or AMP-activated protein kinase.
AMPK acts as a cellular energy sensor. When cellular energy availability drops, AMPK helps shift metabolism toward processes that generate energy while reducing processes that consume large amounts of it.
In the original MOTS-C discovery experiments, the peptide altered folate and purine metabolism, increased the AICAR-related signal, and activated AMPK. These changes were associated with increased glucose utilization in skeletal muscle and improved insulin sensitivity in mice. (Lee et al., 2015, Cell Metabolism)
The MOTS-C peptide also appears responsive to exercise.
In a 2021 study, Reynolds and colleagues found that endogenous MOTS-C increased in skeletal muscle and circulation after exercise in humans. In mice, experimental MOTS-C administration improved physical performance and metabolic flexibility across young, middle-aged, and older animals. (Reynolds et al., 2021, Nature Communications)
However, another human exercise study produced a more nuanced result. D’Souza and colleagues found that acute endurance exercise increased circulating mitochondrial-derived peptides overall, while MOTS-C showed a trend toward an increase rather than a uniformly significant response across every measurement. (D’Souza et al., 2021, American Journal of Physiology – Endocrinology and Metabolism)
Together, these studies suggest that MOTS-C participates in exercise-responsive metabolism, but its behavior depends on the experimental conditions and measurement method.
What Does Current Research Say About MOTS-C Peptide?
The strongest intervention evidence for the MOTS-C peptide still comes from preclinical research.
Metabolism and Insulin Sensitivity
In the original 2015 mouse experiments, researchers used MOTS-C in metabolic models and reported improved glucose utilization, insulin sensitivity, and protection against high-fat-diet-induced metabolic dysfunction. (Lee et al., 2015, Cell Metabolism)
These findings established the initial hypothesis that MOTS-C could function as a mitochondrial regulator of metabolic homeostasis.
Later research expanded the discussion beyond glucose alone. Reviews of MOTS-C biology have highlighted links with lipid metabolism, skeletal-muscle signaling, mitochondrial stress responses, and energy balance. (Lee, Kim & Cohen, 2016, Free Radical Biology and Medicine)
Exercise and Age-Related Physical Decline
Exercise research has generated some of the most striking animal findings.
In the 2021 Nature Communications study, systemic MOTS-C administration increased running capacity in young mice and improved physical performance in middle-aged and old mice. Researchers also reported improvements in gait, grip strength, metabolic flexibility, and muscle-related measures in aged animals. (Reynolds et al., 2021, Nature Communications)
These results have contributed to interest in MOTS-C and healthy-aging research.
But it is important not to translate an improvement in mouse treadmill performance directly into claims of improved human athletic performance.
Cellular Effects Are Not Always Positive
Newer research also shows why the MOTS-C peptide should not simply be described as universally “regenerative.”
In 2026, Xing and colleagues investigated MOTS-C in human adipose-derived mesenchymal stromal cells. MOTS-C activated several metabolic signaling pathways, but it also blunted some reparative functions in the experimental system. (Xing et al., 2026, Inflammation and Regeneration)
This finding is useful because it shows that MOTS-C activity may vary according to cell type, metabolic state, and experimental context.
What Do We Know About MOTS-C Research in Humans?
Human research exists, but most studies have examined naturally occurring MOTS-C levels rather than administering the peptide as an intervention.
In 2018, Cataldo and colleagues compared circulating MOTS-C in lean and obese adults. Plasma levels were similar between the groups overall, but relationships between MOTS-C and insulin-sensitivity markers differed according to metabolic status. (Cataldo et al., 2018, Journal of Investigative Medicine)
More recent research has made the picture even more complex.
Yoon and colleagues studied adults with and without obesity and found higher circulating MOTS-C concentrations in participants with obesity. MOTS-C was associated with BMI and insulin resistance, and concentrations remained largely unchanged despite substantial weight reduction after bariatric surgery. (Yoon et al., 2025, Journal of Clinical & Translational Endocrinology)
These findings contrast with some earlier studies that reported lower MOTS-C concentrations in specific populations with obesity. For example, research in children and adolescents found lower circulating MOTS-C particularly among obese male participants. (Duan et al., 2018, Pediatric Diabetes)
That inconsistency is important. Circulating MOTS-C may vary according to age, sex, insulin resistance, disease severity, assay methods, and other metabolic factors.
Are Human Intervention Trials Underway?
Yes, but the clinical evidence is still developing.
As of September 2026, ClinicalTrials.gov lists MOTS-MET (NCT07505745), a recruiting randomized Phase 2 study designed to evaluate investigational MOTS-C in approximately 120 adults with prediabetes and overweight or obesity.
The trial is examining whether 12 weeks of MOTS-C administration can influence insulin sensitivity, HbA1c, fasting glucose, body weight, and other metabolic measures. No results have yet been posted. (MOTS-MET Phase 2 Study, ClinicalTrials.gov)
This study is important because it may provide direct human intervention evidence rather than simply measuring endogenous peptide concentrations.
Interested in exploring this compound further? Learn more about MOTS-C 10mg for research purposes.
FAQ About MOTS-C Peptide
Is MOTS-C naturally produced by the body?
Yes. Endogenous MOTS-C peptide has been detected in human tissues and circulation. Its sequence originates from mitochondrial DNA, which distinguishes it from most conventional peptide hormones.
Is MOTS-C related to AMPK?
Yes. AMPK activation is one of the most consistently discussed mechanisms in MOTS-C research. Both the original metabolic research and later nuclear-signaling studies link MOTS-C activity with AMPK-dependent metabolic adaptation.
Does MOTS-C improve exercise performance?
Experimental MOTS-C improved physical performance in mice, while human studies show that endogenous MOTS-C can respond to exercise. However, current evidence does not establish that administered MOTS-C improves athletic performance in humans.
Is there an established human MOTS-C dose?
No validated human dosing protocol has been established.
Animal studies have used experimental doses such as 5 mg/kg and 15 mg/kg in mice, depending on the research model. These values describe controlled preclinical experiments and should not be converted directly into human dosing recommendations.
The ongoing MOTS-MET Phase 2 study should provide more useful information on human administration, but results are not yet available.
Is MOTS-C proven for weight loss?
No. The original animal research found protection against diet-induced obesity and metabolic dysfunction, but observational human studies have primarily examined endogenous MOTS-C levels. These findings do not establish MOTS-C as a proven human weight-loss treatment.
What is the biggest gap in MOTS-C research?
The largest gap is clinical translation.
Researchers have substantial mechanistic and animal evidence involving metabolism, stress responses, and physical function, but controlled human intervention evidence remains limited. Even recent human studies mainly measure natural circulating MOTS-C rather than the effects of administering it.
For now, the MOTS-C peptide is best described as an intriguing mitochondrial-derived signaling peptide with strong preclinical metabolic evidence and an emerging—but still incomplete—human research base.
If you are evaluating mitochondrial-derived peptides for laboratory investigation, visit Research Peptides Canada to explore research-use-only compounds and available analytical documentation. When reviewing MOTS-C research, keep animal intervention findings, endogenous human measurements, and controlled human treatment data clearly separated.
Disclaimer: The information and products discussed on this website are intended strictly for laboratory research and educational purposes only. They are not intended for human or veterinary use, diagnosis, treatment, prevention, or any form of clinical application.
6 Comments
I really enjoyed the explanation of why MOTS-C is different from more conventional peptides, particularly its origin from mitochondrial DNA. The connection between MOTS-C, AMPK, and cellular stress responses was also very interesting. I’d be curious to see how much of this mechanism can eventually be confirmed in human intervention studies.
This was a great overview of the current MOTS-C research, especially the distinction between animal studies and research measuring naturally occurring MOTS-C in humans. I appreciated that the article didn’t overstate the exercise and metabolic findings. Do you think the ongoing Phase 2 research could provide a much clearer picture of its potential?
I found the section about the inconsistent human MOTS-C findings particularly interesting. It shows how factors like age, sex, metabolic status, and even assay methods can make the research harder to interpret. I think direct human intervention data will be important for determining whether the promising preclinical findings translate beyond laboratory models.